Furthermore, in the WOEST trial463 and the 4 DOAC AF PCI trials466, 467, 468, 469 as described above, the patients assigned to the dual therapy group were de‐escalated from a triple therapy to a dual therapy with a DOAC plus P2Y12 inhibitor by cessation of aspirin in the periprocedural phase (maximum 2 weeks in the AUGUSTUS trial) after the PCI, which strongly supported the clinical acceptability of an early termination of aspirin after PCI. This evidence concerns the gene P2RY12 and atrial fibrillation.